Total Payments
$144,010
2024 Payments
$23,498
Companies
21
Transactions
316
Medicare Patients
2,880
Medicare Billing
$318,775
Payment Breakdown by Category
Other$121,958 (84.7%)
Travel$14,067 (9.8%)
Food & Beverage$7,347 (5.1%)
Consulting$600.00 (0.4%)
Education$37.76 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $121,958 | 43 | 84.7% |
| Travel and Lodging | $14,067 | 54 | 9.8% |
| Food and Beverage | $7,347 | 215 | 5.1% |
| Consulting Fee | $600.00 | 1 | 0.4% |
| Education | $37.76 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $94,811 | 172 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $46,153 | 42 | $0 (2024) |
| Celgene Corporation | $1,461 | 23 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $398.20 | 18 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $326.53 | 19 | $0 (2024) |
| CONMED Corporation | $158.36 | 1 | $0 (2019) |
| Janssen Biotech, Inc. | $141.70 | 7 | $0 (2024) |
| Merck Sharp & Dohme LLC | $85.88 | 5 | $0 (2022) |
| Allergan Inc. | $84.70 | 5 | $0 (2018) |
| Prometheus Laboratories Inc. | $59.11 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,498 | 60 | ABBVIE INC. ($17,029) |
| 2023 | $35,250 | 79 | ABBVIE INC. ($20,658) |
| 2022 | $35,500 | 60 | E.R. Squibb & Sons, L.L.C. ($19,361) |
| 2021 | $16,256 | 24 | AbbVie Inc. ($8,563) |
| 2020 | $2,509 | 6 | AbbVie Inc. ($2,494) |
| 2019 | $12,827 | 24 | AbbVie, Inc. ($12,581) |
| 2018 | $17,900 | 45 | AbbVie, Inc. ($17,560) |
| 2017 | $271.38 | 18 | AbbVie, Inc. ($93.50) |
All Payment Transactions
316 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: Gastroenterology | ||||||
| 12/18/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $22.17 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/18/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $6.49 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/03/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $103.45 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,875.00 | General |
| Category: IMMUNOLOGY | ||||||
| 09/27/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $71.69 | General |
| Category: IMMUNOLOGY | ||||||
| 09/27/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $41.80 | General |
| Category: IMMUNOLOGY | ||||||
| 09/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $80.49 | General |
| Category: IMMUNOLOGY | ||||||
| 08/28/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Education | In-kind items and services | $15.45 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/20/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $26.85 | General |
| Category: IMMUNOLOGY | ||||||
| 08/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,025.00 | General |
| Category: IMMUNOLOGY | ||||||
| 08/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,025.00 | General |
| Category: IMMUNOLOGY | ||||||
| 08/09/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $21.09 | General |
| Category: THERAPY FOR CSID | ||||||
| 08/07/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $100.57 | General |
| Category: IMMUNOLOGY | ||||||
| 08/07/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $100.57 | General |
| Category: IMMUNOLOGY | ||||||
| 08/07/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $79.06 | General |
| Category: IMMUNOLOGY | ||||||
| 08/07/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $79.06 | General |
| Category: IMMUNOLOGY | ||||||
| 08/07/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $62.00 | General |
| Category: IMMUNOLOGY | ||||||
| 08/07/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $62.00 | General |
| Category: IMMUNOLOGY | ||||||
| 07/26/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $424.57 | General |
| Category: IMMUNOLOGY | ||||||
| 07/26/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $424.57 | General |
| Category: IMMUNOLOGY | ||||||
| 07/26/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $224.68 | General |
| Category: IMMUNOLOGY | ||||||
| 07/26/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $224.68 | General |
| Category: IMMUNOLOGY | ||||||
| 07/26/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $171.72 | General |
| Category: IMMUNOLOGY | ||||||
| 07/26/2024 | ABBVIE INC. | SKYRIZI (Biological) | Travel and Lodging | In-kind items and services | $171.72 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 718 | 820 | $657,885 | $82,952 |
| 2022 | 12 | 906 | 1,011 | $733,430 | $100,865 |
| 2021 | 12 | 768 | 868 | $501,392 | $85,745 |
| 2020 | 13 | 488 | 559 | $316,120 | $49,213 |
Total Patients
2,880
Total Services
3,258
Medicare Billing
$318,775
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 143 | 146 | $239,440 | $26,452 | 11.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 177 | 269 | $61,870 | $23,926 | 38.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 114 | 115 | $165,025 | $8,179 | 5.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 74 | 79 | $12,245 | $5,088 | 41.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 65 | 66 | $76,560 | $4,606 | 6.0% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 23 | 23 | $28,175 | $3,037 | 10.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 25 | 25 | $9,125 | $2,743 | 30.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 20 | $6,500 | $2,626 | 40.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 37 | 37 | $9,065 | $2,389 | 26.4% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 12 | 12 | $13,860 | $1,989 | 14.3% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 12 | 12 | $13,860 | $1,720 | 12.4% |
| 45381 | Injection beneath lining of large bowel using a flexible endoscope | Facility | 2023 | 16 | 16 | $22,160 | $197.44 | 0.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 202 | 286 | $65,780 | $26,072 | 39.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 99 | 99 | $162,360 | $19,196 | 11.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 144 | 144 | $206,640 | $12,599 | 6.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 63 | 63 | $22,995 | $8,082 | 35.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 94 | 94 | $23,030 | $7,370 | 32.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 90 | 94 | $109,040 | $7,109 | 6.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 95 | 107 | $16,585 | $6,947 | 41.9% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 46 | 49 | $60,025 | $5,884 | 9.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 25 | 27 | $8,775 | $3,749 | 42.7% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 14 | 14 | $16,170 | $2,426 | 15.0% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 11 | 11 | $10,175 | $991.79 | 9.7% |
| 45381 | Injection beneath lining of large bowel using a flexible endoscope | Facility | 2022 | 23 | 23 | $31,855 | $439.38 | 1.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 184 | 254 | $58,420 | $25,361 | 43.4% |
About Dr. Leon Mclean, MD
Dr. Leon Mclean, MD is a Gastroenterology healthcare provider based in Derry, New Hampshire. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1457495806.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Leon Mclean, MD has received a total of $144,010 in payments from pharmaceutical and medical device companies, with $23,498 received in 2024. These payments were reported across 316 transactions from 21 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($121,958).
As a Medicare-enrolled provider, Mclean has provided services to 2,880 Medicare beneficiaries, totaling 3,258 services with total Medicare billing of $318,775. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Derry, NH
- Active Since 02/19/2007
- Last Updated 03/08/2017
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1457495806
Products in Payments
- ZEPOSIA (Drug) $47,015
- SKYRIZI (Biological) $33,331
- Humira (Biological) $27,644
- RINVOQ (Biological) $19,883
- HUMIRA (Biological) $6,910
- ENTYVIO (Biological) $223.94
- CONMED GENERATORS (Device) $158.36
- STELARA (Biological) $141.70
- XIFAXAN (Drug) $140.17
- MAVYRET (Drug) $130.86
- LINZESS (Drug) $125.44
- XIFAXANIBSD (Drug) $93.61
- Amitiza (Drug) $76.14
- CREON (Drug) $74.55
- VIBERZI (Drug) $55.26
- MOTEGRITY (Drug) $53.73
- TRULANCE (Drug) $48.41
- Cimzia (Drug) $48.20
- RELISTOR ORAL (Drug) $46.49
- GATTEX (Drug) $41.59
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.